{"id":"W3200056356","doi":"10.1055/a-1647-9896","title":"Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study","year":2021,"lang":"en","type":"article","venue":"Thrombosis and Haemostasis","topic":"Venous Thromboembolism Diagnosis and Management","field":"Medicine","cited_by":59,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"Cilag; LEO Pharma; Ipsen; Pfizer; Vifor Pharma; Amgen; ZonMw; Daiichi Sankyo Europe; Bayer HealthCare; Sanofi; Servier; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Apixaban; Regimen; Hazard ratio; Pulmonary embolism; Randomized controlled trial; Surgery; Clinical endpoint; Venous thrombosis; Internal medicine; Thrombosis; Confidence interval; Warfarin; Atrial fibrillation; Rivaroxaban","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001818234,0.0003294885,0.001144794,0.0001001649,0.0002240488,0.0000515877,0.00008611069,0.00007060106,0.0001025095],"category_scores_gemma":[0.00003012182,0.000180738,0.00005148937,0.0004966388,0.0001779731,0.0001025859,0.00009544606,0.00009460615,7.544311e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001956477,"about_ca_system_score_gemma":0.000355374,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000937467,"about_ca_topic_score_gemma":0.001822241,"domain_scores_codex":[0.9980661,0.0001893377,0.0003864097,0.0005336177,0.0004794617,0.0003450997],"domain_scores_gemma":[0.9988902,0.00009979507,0.0002231912,0.0004423007,0.0002241145,0.0001204301],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00328899,0.05600033,0.873799,0.0004209691,0.006666977,0.0001398578,0.02349286,0.0002368447,0.003583352,0.0002410336,0.0008325626,0.03129722],"study_design_scores_gemma":[0.01045135,0.006362723,0.9756689,0.0004692459,0.001700177,0.000008121501,0.002830097,0.00008470547,0.002118179,0.00002369308,0.00004021981,0.0002425778],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955493,0.0004362757,0.000013094,0.0009478642,0.00006404025,0.002833821,0.00007573753,0.00002414986,0.00005573468],"genre_scores_gemma":[0.9965493,0.002269533,0.0005333453,0.0002285514,0.00002191879,0.0002438675,0.00004254398,0.0000424668,0.00006846768],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1018699,"threshold_uncertainty_score":0.7370283,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05993991657109114,"score_gpt":0.3034428731773453,"score_spread":0.2435029566062542,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}